Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

78512

	registered interest
	date	16/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoarthritis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people have suffered complications following knee and hip operations related to osteoarthritis in the last five years.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	206190
	answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>This information is not available. Although some information on post-operative complications experienced by osteoporosis patients following surgery of the hip and knee is available via the Health and Social Care Information Centre’s Patient Reported Outcome Measures (PROMs) data collection, this only covers hip and knee replacement, and not the full range of surgical interventions. In addition to this, as PROMs is a voluntary reporting system the data published does not reflect the total number of osteoporosis patients having complications for all hip and knee replacements. More information on PROMS data can be found at the following link:</p><p> </p><p><a href="http://www.hscic.gov.uk/proms" target="_blank">www.hscic.gov.uk/proms</a></p><p><strong> </strong></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 22/07/2014 13:39:02 answering member 1439 label Biography information for Norman Lamb
	tabling member	4034 label Biography information for Yvonne Fovargue

90496

	registered interest
	date	03/09/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the next step is in the commissioning of a specialised service after a positive recommendation by the Prescribed Specialised Services Advisory Group (PSSAG); whether services recommended for commissioning by PSSAG in September 2014 will be funded from April 2015; when the PSSAG recommendations on the application for a specialised service for Alpha-1 Antitrypsin Deficiency will be published; and if he will make a statement.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	208035
	answer	answer is ministerial correction date of answer 10/09/2014 answer text <p> </p><p>The Prescribed Specialised Services Advisory Group (PSSAG) is a Department of Health expert committee which provides advice to Ministers on which services should be prescribed in regulations for national commissioning by the NHS Commissioning Board (NHS England).</p><p> </p><p> </p><p> </p><p>PSSAG makes recommendations to Ministers, who are obliged under section 3B of the National Health Service Act 2006 to take appropriate advice and to consult with NHS England before making regulations to prescribe particular services as specialised services for NHS England commissioning. Decisions on the timing of any changes to commissioning responsibilities will take account of advice from PSSAG and any consultation response from NHS England.</p><p> </p><p> </p><p> </p><p>Where a service is prescribed for national commissioning, NHS England becomes responsible for making decisions on the commissioning of that service, including funding of specific interventions as part of that service. We understand from NHS England that where it becomes the responsible commissioner for a service, it considers the funding priority of the service through its Clinical Priorities Advisory Group.</p><p> </p><p> </p><p> </p><p>We understand the Alpha 1 Alliance has worked with NHS England and the Specialised Respiratory Clinical Reference Group to develop a proposal for the national commissioning of services for patients with alpha 1-antitrypsin deficiency, which will be put to PSSAG for consideration at its next meeting on 30 September. A report containing PSSAG’s recommendations will be published once Ministers have made decisions on any associated changes.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/09/2014 12:18:26 answering member 3918 label Biography information for Jane Ellison
	tabling member	4034 label Biography information for Yvonne Fovargue

890101

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accident and Emergency Departments: Closures
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many A&E units closed in each constituency in each year between 2010 and 2016.
	tabling member constituency	Normanton, Pontefract and Castleford
	tabling member printed	Yvette Cooper
	uin	137151
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>Changes to the local NHS services are a matter for the local National Health Service, and form part of the commissioning process. This includes working with local people and with clinicians to ensure that changes are in the best interests of patients. Records of this activity are not held centrally.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 137152 question first answered 26/04/2018 16:39:29 answering member 4095 label Biography information for Steve Barclay
	tabling member	420 label Biography information for Yvette Cooper

890102

	registered interest
	date	23/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Closures
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many hospitals closed in each constituency in each year between 2010 and 2016.
	tabling member constituency	Normanton, Pontefract and Castleford
	tabling member printed	Yvette Cooper
	uin	137152
	answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>Changes to the local NHS services are a matter for the local National Health Service, and form part of the commissioning process. This includes working with local people and with clinicians to ensure that changes are in the best interests of patients. Records of this activity are not held centrally.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 137151 question first answered 26/04/2018 16:39:29 answering member 4095 label Biography information for Steve Barclay
	tabling member	420 label Biography information for Yvette Cooper

910220

	registered interest
	date	23/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Closures
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the (a) names, (b) postcodes and (c) year of closure of the hospitals that closed between 2010 and 2018.
	tabling member constituency	Normanton, Pontefract and Castleford
	tabling member printed	Yvette Cooper
	uin	147336
	answer	answer is ministerial correction date of answer 04/06/2018 answer text <p>The information is not held centrally.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 04/06/2018 09:52:13 answering member 4095 label Biography information for Steve Barclay
	tabling member	420 label Biography information for Yvette Cooper

910221

	registered interest
	date	23/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accident and Emergency Departments: Closures
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the (a) names, (b) postcodes and (c) year of closure of the A&Es that closed between 2010 and 2018.
	tabling member constituency	Normanton, Pontefract and Castleford
	tabling member printed	Yvette Cooper
	uin	147337
	answer	answer is ministerial correction date of answer 04/06/2018 answer text <p>This information is not held centrally.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 04/06/2018 09:51:11 answering member 4095 label Biography information for Steve Barclay
	tabling member	420 label Biography information for Yvette Cooper

147552

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that (a) NHS England continues to routinely assess the quality and safety of local breast cancer multi-disciplinary teams and network groups as part of the National Cancer Peer Review programme and (b) this information is made available to patients through the My Cancer Treatment website.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	213933
	answer	answer is ministerial correction date of answer 20/11/2014 answer text <p>NHS England is currently reviewing the National Cancer Peer Review Programme with a view to considering how its success might be extended into other new areas of specialised commissioning. Further details, including how the public can access information on the quality of clinical services, will be available following the completion of the review.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/11/2014 16:45:59 answering member 3918 label Biography information for Jane Ellison
	tabling member	3924 label Biography information for Yasmin Qureshi

147553

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure routine access to tamoxifen and raloxifene for the indication of chemoprevention in the UK.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	213936
	answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Information on the number of women treated with tamoxifen and raloxifene for the treatment or prevention of breast cancer is not collected centrally.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 213934 question first answered 19/11/2014 15:55:55 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

147554

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what proportion of women who are eligible for tamoxifen and raloxifene are offered this treatment.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	213934
	answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Information on the number of women treated with tamoxifen and raloxifene for the treatment or prevention of breast cancer is not collected centrally.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 213936 question first answered 19/11/2014 15:55:55 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

147559

	registered interest
	date	10/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to ensure that clinically-proven, cost-effective drugs are made routinely available to all when they are shown to be of use in a new indication but are off-patent.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	214030
	answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>We support appropriate use of off-patent medicines in areas where the evidence suggests that they can deliver patient benefit. Doctors can already prescribe a drug outside its licensed indications where they judge it to be the most clinically appropriate treatment for an individual patient. Medicines are routinely prescribed legally, safely and appropriately outside their licensed indications to large numbers of National Health Service patients.</p><p> </p><p> </p><p> </p><p>We are in the process of setting up a round-table discussion with key stakeholders, NHS England and the National Institute for Health and Care Excellence to review the evidence and explore opportunities to work together to better support appropriate use of these medicines.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 19/11/2014 16:02:12 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi